WuXi XDC and LegoChem sign MoD to make more ADCs accessible to patients

XDC will provide a full range of development and manufacturing services in one centralised region

China's WuXi XDC, a recently established CDMO, and South Korea-based LegoChem Biosciences, have signed a Memorandum of Understanding (MoU) to form a strategic partnership regarding the development and manufacturing of antibody-drug conjugates (ADCs).

The partnership grants LegoChem access to XDC's integrated services in monoclonal antibody (mAb), linker, payload, analytical and formulation development, as well as ADC drug substance and drug product development and manufacturing.

Last month, WuXi Biologics and WuXi STA (a subsidiary of WuXi AppTec) formed the joint venture CDMO to provide end-to-end contract development and manufacturing of bioconjugates including ADCs.

According to Dr Chris Chen, CEO of WuXi Biologics and Chairman of WuXi XDC, combining the capabilities and capabilities of both companies, XDC will provide a "one-stop service" for global partners; thus expediting development and lowering costs.

XDC's CEO Dr Jimmy Li said the company has witnessed increasing outsourced demand for ADCs as more ADC programs advance towards clinical trials and commercial production.